Список литературы к Главе 12

1. Никитин Е.А., Халлек M., Байков В.В., Бакиров Б.А., Бессмельцев С.С., Загоскина Т.П. и др. Российские клинические рекомендации по диагностике и лечению хронического лимфолейкоза (версия 2012 г) // Современная онкология. 2012. № 4. С. 10–14.

2. Galton D.A. et al. The use of chlorambucil and steroids in the treatment of chronic lymphocytic leukaemia // Br. J. Haematol. 1961. Vol. 7. P. 73–98.

3. Кассирский И.А., Волкова М.А. Основные проблемы хронического лимфолейкоза // Терапевтический архив. 1970. Т. 42, № 1. С. 8–15.

4. Бессмельцев С.С., Бялик Т.Е., Волкова М.А., Голубева М.Е., Загоскина Т.П., Зарицкий А.Ю. и др. Рекомендации по обследованию и лечению больных В­клеточным хроническим лимфолейкозом // Современная онкология. 2008. Т. 10, № 4. С. 10–22.

5. Effectiveness of «CHOP» regimen in advanced untreated chronic lymphocytic leukaemia. French Cooperative Group on Chronic Lymphocytic Leukaemia // Lancet. 1986. Vol. 1, N 8494. P. 1346–1349.

6. CHOP regimen versus intermittent chlorambucil­prednisone in stage B chronic lymphocytic leukemia. Short term results from a randomized clinical trial. French Cooperative Group on Chronic Lymphocytic Leukemia // Nouv. Rev. Fr. Hematol. 1988. Vol. 30, N 5–6. P. 449–452.

7. Long­term results of the CHOP regimen in stage C chronic lymphocytic leukaemia. French Cooperative Group on Chronic Lymphocytic Leukaemia // Br. J. Haematol. 1989. Vol. 73, N 3. P. 334–340.

8. A randomized clinical trial of chlorambucil versus COP in stage B chronic lymphocytic leukemia. The French Cooperative Group on Chronic Lymphocytic Leukemia // Blood. 1990. Vol. 75, N 7. P. 1422–1425.

9. Leblond V. et al. Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide­doxorubicin­prednisone in 92 patients with Waldenstrom macroglobulinemia in first relapse or with primary refractory disease // Blood. 2001. Vol. 98, N 9. P. 2640–2644.

10. Kimby E. et al. A systematic overview of chemotherapy effects in B­cell chronic lymphocytic leukaemia // Acta Oncol. 2001. Vol. 40, N 2–3. P. 224–230.

11. Langerbeins P. et al. Poor efficacy and tolerability of R­CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation // Am. J. Hematol. 2014. Vol. 89, N 12. P. E239–E243.

12. Cramer P. et al. Second­line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group // Leuk. Lymphoma. 2013. Vol. 54, N 8. P. 1821–1822.

13. Keating M.J. et al. Fludarabine phosphate: a new active agent in hematologic malignancies // Semin. Hematol. 1994. Vol. 31, N 1. P. 28–39.

14. Keating M.J. et al. The expanding role of fludarabine in hematologic malignancies // Leuk. Lymphoma. 1994. Vol. 14, suppl. 2. P. 11–16.

15. Keating M.J. et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia // J. Clin. Oncol. 2005. Vol. 23, N 18. P. 4079–4088.

16. Rai K.R. et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia // N. Engl. J. Med. 2000. Vol. 343, N 24. P. 1750–1757.

17. Comparison of fludarabine, cyclophosphamide/doxorubicin/prednisone, and cyclophosphamide/doxorubicin/vincristine/prednisone in advanced forms of chronic lymphocytic leukemia: preliminary results of a controlled clinical trial. The French Cooperative Group on Chronic Lymphocytic Leukemia // Semin. Oncol. 1993. Vol. 20, N 5, suppl. 7. P. 21–23.

18. Hallek M., Eichhorst B.F. Chemotherapy combination treatment regimens with fludarabine in chronic lymphocytic leukemia // Hematol. J. 2004. Vol. 5, suppl. 1. P. S20–S30.

19. Bosch F. et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia // Br. J. Haematol. 2002. Vol. 119, N 4. P. 976–984.

20. Hendry L. et al. Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non­Hodgkin's lymphoma // Leuk. Lymphoma. 2004. Vol. 45, N 5. P. 945–950.

21. Catovsky D. et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial // Lancet. 2007. Vol. 370, N 9583. P. 230–239.

22. Eichhorst B.F. et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first­line therapy of younger patients with chronic lymphocytic leukemia // Blood. 2006. Vol. 107, N 3. P. 885–891.

23. Flinn I.W. et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997 // J. Clin. Oncol. 2007. Vol. 25, N 7. P. 793–798.

24. Bellosillo B. et al. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B­cell chronic lymphocytic leukemia // Blood. 1999. Vol. 94, N 8. P. 2836–2843.

25. Eichhorst B.F. et al. First­line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia // Blood. 2009. Vol. 114, N 16. P. 3382–3391.

26. Ozegowski W., Krebs D. IMET 3393,(­[1­Methyl­5­(b­bis­chloroethyl)­amino­benzimidazolyl­(2)]­butyric acid hydrochloride, a new cytostatic agent from among the series of benzimidazole mustard compounds // Zbl. Pharm. 1971. Vol. 110. P. 1013–1019.

27. Knauf W.U. et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia // J. Clin. Oncol. 2009. Vol. 27, N 26. P. 4378–4384.

28. Moreton P., Hillmen P. Alemtuzumab therapy in B­cell lymphoproliferative disorders // Semin. Oncol. 2003. Vol. 30, N 4. P. 493–501.

29. Moreton P. et al. Eradication of minimal residual disease in B­cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival // J. Clin. Oncol. 2005. Vol. 23, N 13. P. 2971–2979.

30. Karlsson C. et al. Alemtuzumab as first­line therapy for B­cell chronic lymphocytic leukemia: long­term follow­up of clinical effects, infectious complications and risk of Richter transformation // Leukemia. 2006. Vol. 20, N 12. P. 2204–2207.

31. Montillo M. et al. Alemtuzumab in the treatment of fludarabine refractory B­cell chronic lymphocytic leukemia (CLL) // Biol. Targets Ther. 2008. Vol. 2, N 1. P. 41–52.

32. Hillmen P. et al. Alemtuzumab compared with chlorambucil as first­line therapy for chronic lymphocytic leukemia // J. Clin. Oncol. 2007. Vol. 25, N 35. P. 5616–5623.

33. Lepretre S. et al. Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial // Blood. 2012. Vol. 119, N 22. P. 5104–5110.

34. Stilgenbauer S. et al. Subcutaneous alemtuzumab in fludarabine­refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group // J. Clin. Oncol. 2009. Vol. 27, N 24. P. 3994–4001.

35. Dreger P. et al. Allogeneic stem cell transplantation provides durable disease control in poor­risk chronic lymphocytic leukemia: long­term clinical and MRD results of the German CLL Study Group CLL3X trial // Blood. 2010. Vol. 116, N 14. P. 2438–2447.

36. Hallek M. et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute­Working Group 1996 guidelines // Blood. 2008. Vol. 111, N 12. P. 5446–5456.

37. Cragg M.S. et al. The biology of CD20 and its potential as a target for mAb therapy // Curr. Dir. Autoimmun. 2005. Vol. 8. P. 140–174.

38. Ginaldi L. et al. Levels of expression of CD19 and CD20 in chronic B cell leukaemias // J. Clin. Pathol. 1998. Vol. 51, N 5. P. 364–369.

39. Press O.W. et al. Retention of B­cell­specific monoclonal antibodies by human lymphoma cells // Blood. 1994. Vol. 83, N 5. P. 1390–1397.

40. Gupta N., DeFranco A.L. Lipid rafts and B cell signaling // Semin. Cell Dev. Biol. 2007. Vol. 18, N 5. P. 616–626.

41. Chan H.T. et al. CD20­induced lymphoma cell death is independent of both caspases and its redistribution into triton X­100 insoluble membrane rafts // Cancer Res. 2003. Vol. 63, N 17. P. 5480–5489.

42. Alduaij W. et al. Novel type II anti­CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin­dependent, lysosome­mediated cell death in B­cell malignancies // Blood. 2011. Vol. 117, N 17. P. 4519–4529.

43. Cragg M.S. CD20 antibodies: doing the time warp // Blood. 2011. Vol. 118, N 2. P. 219–220.

44. Beers S.A. et al. Antigenic modulation limits the efficacy of anti­CD20 antibodies: implications for antibody selection // Blood. 2010. Vol. 115, N 25. P. 5191–5201.

45. Goede V. et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions // N. Engl. J. Med. 2014. Vol. 370, N 12. P. 1101–1110.

46. Keating M., O’Brien S. High­dose rituximab therapy in chronic lymphocytic leukemia // Semin. Oncol. 2000. Vol. 27, N 6. Suppl. 12. P. 86–90.

47. Manshouri T. et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance // Blood. 2003. Vol. 101, N 7. P. 2507–2513.

48. O’Brien S.M. et al. Rituximab dose­escalation trial in chronic lymphocytic leukemia // J. Clin. Oncol. 2001. Vol. 19, N 8. P. 2165–2170.

49. Di Gaetano N. et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone // Br. J. Haematol. 2001. Vol. 114, N 4. P. 800–809.

50. Byrd J.C. et al. Addition of rituximab to fludarabine may prolong progression­free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011 // Blood. 2005. Vol. 105, N 1. P. 49–53.

51. Hallek M. et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open­label, phase 3 trial // Lancet. 2010. Vol. 376, N 9747. P. 1164–1174.

52. Bottcher S. et al. Standardized MRD flow and ASO IGH RQ­PCR for MRD quantification in CLL patients after rituximab­containing immunochemotherapy: a comparative analysis // Leukemia. 2009. Vol. 23, N 11. P. 2007–2017.

53. Никитин Е.А. Дифференцированная терапия хронического лимфолейкоза : дис. … д-ра мед. наук. Москва, 2014. 222 с.

54. Thompson P.A. et al. Serial minimal residual disease (MRD) monitoring during first­line FCR treatment for CLL may direct individualized therapeutic strategies // Leukemia. 2018. Vol. 32, N 11. P. 2388–2398.

55. Wilder D.D., Ogden J.L., Jain V.K. Efficacy of fludarabine/mitoxantrone/dexamethasone alternating with CHOP in bulky follicular non­Hodgkin’s lymphoma // Clin. Lymphoma. 2002. Vol. 2, N 4. P. 229–237.

56. Zinzani P.L. et al. Fludarabine­based chemotherapy in untreated mantle cell lymphomas: an encouraging experience in 29 patients // Haematologica. 1999. Vol. 84, N 11. P. 1002–1006.